BBOT (BridgeBio Oncology Therapeutics) OCF Yield %: -19.33 (As of Jul. 06, 2026)


BBOT BridgeBio Oncology Therapeutics Inc BBOT
12 GF Score
Price $8.40
View Full Analysis

What is BridgeBio Oncology Therapeutics OCF Yield %?

BridgeBio Oncology Therapeutics BBOT +3.70% 12 OCF Yield % is -19.33 as of Jul. 06, 2026. GuruFocus rates BBOT with a GF Score™ of 12/100. Among 1,410 Biotechnology companies, BridgeBio Oncology Therapeutics ranks worse than 68.58% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, BridgeBio Oncology Therapeutics's Trailing 12-Month Cash Flow from Operations is $-130.21 Mil, and Market Cap is $672.90 Mil. Therefore, BridgeBio Oncology Therapeutics's OCF Yield % for today is -19.33%.

The historical rank and industry rank for BridgeBio Oncology Therapeutics's OCF Yield % or its related term are showing as below:

BBOT' s OCF Yield % Range Over the Past 10 Years
Min: -20.08   Med: 0   Max: -18.93
Current: -19.33

During the past 3 years, the highest OCF Yield % of BridgeBio Oncology Therapeutics was -18.93%. The lowest was -20.08%. And the median was %.

BBOT's OCF Yield % is ranked worse than
68.58% of 1410 companies
in the Biotechnology industry
Industry Median: -7.975 vs BBOT: -19.33

BridgeBio Oncology Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was %.

BridgeBio Oncology Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

BridgeBio Oncology Therapeutics OCF Yield % Related Terms

BridgeBio Oncology Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for BridgeBio Oncology Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Oncology Therapeutics OCF Yield % Chart

BridgeBio Oncology Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
OCF Yield %
0.00 0.00 -11.37

BridgeBio Oncology Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -12.55 -16.87 -20.04

BBOT vs FTH, MNPR, MDXG: OCF Yield % Comparison

For the Biotechnology subindustry, BridgeBio Oncology Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BridgeBio Oncology Therapeutics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Oncology Therapeutics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where BridgeBio Oncology Therapeutics's OCF Yield % falls into.


BBOT
12GF Score
BridgeBio Oncology Therapeutics Inc BBOT
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BridgeBio Oncology Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

BridgeBio Oncology Therapeutics's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-113.894 / 1001.49984
=-11.37%

BridgeBio Oncology Therapeutics's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-35.917 * 4 / 716.79655
=-20.04%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -19.33 mean?
BridgeBio Oncology Therapeutics (BBOT) has a OCF Yield % of -19.33 as of Jul. 06, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on BridgeBio Oncology Therapeutics and its competitors. According to the industry distribution chart, BridgeBio Oncology Therapeutics ranks #967 out of 1410 companies in the Biotechnology industry, placing it in the top 68.6%.
Is BridgeBio Oncology Therapeutics' OCF Yield % too high?
BridgeBio Oncology Therapeutics' current OCF Yield % is -19.33. Based on the distribution chart, BridgeBio Oncology Therapeutics ranks #967 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BridgeBio Oncology Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Oncology Therapeutics' OCF Yield % compare to FTH and MNPR?
According to the Biotechnology industry distribution chart, BridgeBio Oncology Therapeutics ranks #967 out of 1410 companies for OCF Yield %. This places BridgeBio Oncology Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on BridgeBio Oncology Therapeutics and its competitors. BridgeBio Oncology Therapeutics's current OCF Yield % is -19.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Oncology Therapeutics stock overvalued right now?
BridgeBio Oncology Therapeutics (BBOT) has a current OCF Yield % of -19.33. The current OCF Yield % is -19.33. BridgeBio Oncology Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For BridgeBio Oncology Therapeutics (BBOT), the current OCF Yield % is -19.33 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BridgeBio Oncology Therapeutics Business Description

Address 256 East Grand Avenue, Suite 104, South San Francisco, CA, USA, 94080
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
12GF Score

Get the complete analysis for BBOT

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.40
Price